Cargando…
Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial
MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta(®)). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta(®). As secondary objectives, the safety and tolerability of MSB11455 and Neulasta(®) were also compared. Healthy...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183238/ https://www.ncbi.nlm.nih.gov/pubmed/32333641 http://dx.doi.org/10.1002/prp2.578 |